logo-loader

CEL-SCI Corporation progressing its Phase 3 head and neck cancer study

Published: 16:06 14 Feb 2019 EST

CEL-SCI Corporation (NYSE American: CVM) CEO Geert Kersten spoke with Proactive Investors at the BIO CEO and Investor Conference in New York. 

CEL-SCI treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with its drug Multikine first, before they receive surgery, radiation and/or chemotherapy.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

58 minutes ago